Nimesulide is a non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties and a specific mode of action.

Nimesulide is indicated for the treatment of acute pain, the symptomatic treatment of painful osteoarthritis and primary dysmenorrhoea.

The recommended oral dose of Nimesulide for adults and adolescents above 12 years is 100 mg twice daily, to be used for the shortest time needed to treat symptoms.

The warnings and contraindications are in line with those of the other drugs of the class. The drug is contraindicated in children below 12 years.

Nimesulide efficacy & safety have been evaluated in over 200 clinical studies in a wide range of conditions characterized by acute pain. In these studies, Nimesulide was found to be at least effective, or superior, to placebo and other NSAIDs, with a particular fast onset of analgesic action.

Nimesulide safety profile is in line with that of the whole NSAID class. Nimesulide shows a superior gastrointestinal safety profile in comparison to other NSAIDs and a low propensity for renal, cardiovascular, skin and hepatic side effects.

Nimesulide post–marketing data and the results of a recent retrospective cohort study showed that the occurrence of hepatic reactions after administration of Nimesulide is a rare event with an incidence comparable to that of all the other NSAIDs.

Nimesulide overall positive benefit/risk profile is supported by about 500 million patients treated worldwide since its first introduction on the market in Italy in 1985 (data as of December 2006).

The therapeutic effects of Nimesulide are the result of its specific mode of action which targets a number of key mediators of the inflammatory process such as: COX-2 mediated prostaglandins, free radicals, proteolytic enzymes and histamine.

Nimesulide has been developed and licensed out by Helsinn Healthcare SA, Switzerland, which acquired the exclusive world-wide rights for the drug in 1976. Only Helsinn's official partners market the original product, granting the highest quality thanks to first-rate and controlled manufacturing processes under GMP rules.

Nimesulide is currently marketed in around 50 countries world-wide under different brand names, and it is among the most prescribed NSAIDs. It is available as tablets, granules, suppositories and in some countries also as oral drops and oral suspension. Nimesulide is also now on the market as topical gel.

The Original Nimesulide registered trademarks in the world are:
Aulin®, Ainex®, Donulide®, Eskaflam®, Mesulid®, Nexen®, Nimed®, Nisulid®, Scaflam®, Scaflan®.

 

The prescription and use in compliance with the approved Summary of Product Characteristics are fundamental to guarantee the safety of all drugs, including Nimesulide. For any question or doubt, please refer to your physician.